journal article·2026-05

Small shift, big impact: How nitrogen position controls risedronate-calcium zeolite interactions

Monika Zielińska, Paulina Lechwar, Katarzyna Gaweł-Bęben, Michael Fischer, Bartosz Orwat, Ireneusz Kownacki, Maria Ratajczak, Mariusz Sandomierski

Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Bone health and treatments · Parathyroid Disorders and Treatments · Bone health and osteoporosis research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (40)

Show source-provided references
1. Bisphosphonates: the first 40years10.1016/j.bone.2011.04.022 ↗
2. Bartl · 2007
3. Bisphosphonates
4. Biomedical applications of bisphosphonates10.1016/j.jconrel.2013.01.032 ↗
5. Clunie · 2014
6. SCOPE 2021: a new scorecard for osteoporosis in Europe10.1007/s11657-020-00871-9 ↗
7. History of risedronate10.1016/j.bone.2020.115407 ↗
8. The impact of bisphosphonates on mortality and cardiovascular risk among osteoporosis patients after cardiovascular disease10.1016/j.jfma.2020.12.014 ↗
9. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy10.1196/annals.1402.089 ↗
10. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy10.1007/s00198-007-0540-8 ↗
11. Osteoporosis: a review of treatment options
12. Osteonecrosis of the jaw in the United States food and drug administration's adverse event reporting system (FAERS)10.1002/jbmr.2693 ↗
13. Bisphosphonate-related osteonecrosis of the jaw in patients with osteoporosis
14. American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis — 2016, endocr
15. UK clinical guideline for the prevention and treatment of osteoporosis10.1007/s11657-017-0324-5 ↗
16. Risedronate transdermal delivery system based on a fumaric copolymer for therapy of osteoporosis10.1016/j.msec.2017.03.147 ↗
17. Biodegradable intranasal nanoparticulate drug delivery system of risedronate sodium for osteoporosis10.3109/10717544.2014.1002947 ↗
18. Crystalline zeolite layers on the surface of titanium alloys in biomedical applications: current knowledge and possible directions of development10.3390/cryst12111520 ↗
19. Bisphosphonate-incorporated coatings for orthopedic implants functionalization
20. Targeted delivery of anti-osteoporosis therapy: Bisphosphonate-modified nanosystems and composites10.1016/j.biopha.2024.116699 ↗
21. In Situ hydrogel with immobilized Mn-Porphyrin for reactive oxygen species scavenging, oxygen generation, and risedronate delivery in bone defect treatment10.1021/acsami.4c08350 ↗
22. EGTA-derived carbon dots with bone-targeting ability: Target-oriented synthesis and calcium affinity10.1021/acsami.3c05184 ↗
23. Calcium zeolites as intelligent carriers in controlled release of bisphosphonates10.1016/j.ijpharm.2020.119117 ↗
24. Calcium montmorillonite as a potential carrier in the release of bisphosphonates10.1039/D1NJ04268H ↗
25. Controlled release of aminomethylenebisphosphonates from a calcium zeolite carrier: investigating the impact of compound structure on sorption and release profiles10.1039/D5MA00371G ↗
26. Comparative analysis of risedronate and its regioisomers synthesized via microwave-assisted method: bone affinity, cytotoxicity, permeability, and therapeutic potential10.1007/s43440-025-00703-y ↗
27. How useful is SBF in predicting in vivo bone bioactivity?10.1016/j.biomaterials.2006.01.017 ↗
28. Stability of simulated body fluids such as blood plasma, artificial urine and artificial saliva10.1016/j.microc.2017.06.004 ↗
29. Neutral red uptake assay for the estimation of cell viability/cytotoxicity10.1038/nprot.2008.75 ↗
30. Experimental and computational study on the Ca2+, Mg2+, Zn2+ and Sr2+ exchanged zeolites as a drug delivery system for fluoroquinolone antibiotic – ciprofloxacin
31. H. Sun, COMPASS: an Ab Initio Force-Field Optimized for Condensed-phase ApplicationssOverview with Details on Alkane and Benzene Compounds, (n.d.).
32. CP2K: an electronic structure and molecular dynamics software package - quickstep: efficient and accurate electronic structure calculations10.1063/5.0007045 ↗
33. A consistent and accurate ab initio parametrization of density functional dispersion correction (DFT-D) for the 94 elements H-Pu10.1063/1.3382344 ↗
34. Gaussian basis sets for accurate calculations on molecular systems in gas and condensed phases10.1063/1.2770708 ↗
35. Pseudopotentials for H to Kr optimized for gradient-corrected exchange-correlation functionals10.1007/s00214-005-0655-y ↗
36. M. Zielińska, Controlled Release of Aminomethylenebisphosphonates from a Calcium Zeolite Carrier: Investigating the Impact of Drug Structure on Sorption and Release Profiles, (n.d.).
37. Silicalite-1 layers as a biocompatible Nano- and micro-structured coating: an in vitro study on MG-63 cells10.3390/ma12213583 ↗
38. Cisplatin loaded polycaprolactone – zeolite nanocomposite scaffolds for bone cancer treatment
39. Risedronate inhibits human osteosarcoma cell invasion10.1186/1756-9966-28-105 ↗
40. Elevated extracellular calcium ions promote proliferation and migration of mesenchymal stem cells via increasing osteopontin expression